Hift RJ, Meissner PN (2005) An analysis of 112 acute porphyric attacks in Cape Town,

South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in

susceptibility and severity. Medicine (Baltimore) 84:48–60

Hurt K, Bilton D (2014) Inhaled interventions in cystic fibrosis: mucoactive and antibiotic

therapies. Respiration 88:441–448

Iorio F, Rittman T, Ge H et al (2013) Transcriptional data: a new gateway to drug repositioning?

Drug Discov Today 18:350–357

Jang GR, Benet LZ (1998) Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharma-

cology 56:150–157

Jiang T, Yu JT, Hu N et al (2014) CD33 in Alzheimer’s disease. Mol Neurobiol 49:529–535

Jones MR, Schrader KA, Shen Y et al (2016) Response to angiotensin blockade with irbesartan in a

patient with metastatic colorectal cancer. Ann Oncol 27:801–806

Kim JH, Scialli AR (2011) Thalidomide: the tragedy of birth defects and the effective treatment of

disease. Toxicol Sci 122:1–6

Kim YH, Beak SH, Charidimou A et al (2016) Discovering new genes in the pathways of common

sporadic neurodegenerative diseases: a bioinformatics approach. J Alzheimers Dis 51:293–312

Koromina M, Pandi M-T, Patrinos GP (2019) Rethinking drug repositioning and development with

artificial intelligence, machine learning, and omics. Omi A J Integr Biol 23:539–548.

Available from: https://www.liebertpub.com/doi/10.1089/omi.2019.0151

Kumar S, Kumar S (2019) Molecular docking: a structure-based approach for drug repurposing. In:

Silico drug design

Kwon OS, Kim W, Cha HJ et al (2019) In silico drug repositioning: from large-scale transcriptome

data to therapeutics. Arch Pharm Res 42:879–889. https://doi.org/10.1007/s12272-019-01176-3

Lau A, So HC (2020) Turning genome-wide association study findings into opportunities for drug

repositioning. Comput Struct Biotechnol J 18:1639–1650

Lavandeira A (2002) Orphan drugs: legal aspects, current situation. Haemophilia 8:194–198

Le DH, Nguyen-Ngoc D (2018) Drug repositioning by integrating known disease-gene and drug-

target associations in a semi-supervised learning model. Acta Biotheor 66:315–331

Lekka E, Deftereos SN, Persidis A et al (2011) Literature analysis for systematic drug repurposing:

a case study from Biovista. Drug Discov Today Ther Strateg 8:103–108

Lexology (2021) The IP Challenge in Patents For Repurposed Drugs and DRPx products.

Available from: https://www.lexology.com/library/detail.aspx?g¼6424901b-c7f4-40bc-8586-

4bdfed07fc33

Li YY, Jones SJM (2012) Drug repositioning for personalized medicine. Genome Med 4:27

Liu H, Lin H, Shen C et al (2020) Drug repositioning for SARS-CoV-2 based on graph neural

network. In: Proc - 2020 IEEE Int Conf Bioinforma Biomed BIBM 2020. Institute of Electrical

and Electronics Engineers Inc., pp 319–322

Mahdian S, Ebrahim-Habibi A, Zarrabi M (2020) Drug repurposing using computational methods

to identify therapeutic options for COVID-19. J Diabetes Metab Disord 19:691–699

Maletic V, Eramo A, Gwin K et al (2017) The role of norepinephrine and its α-adrenergic receptors

in the pathophysiology and treatment of major depressive disorder and schizophrenia: a

systematic review. Front Psychiatry 8:42

March-Vila E, Pinzi L, Sturm N et al (2017) On the integration of in silico drug design methods for

drug repurposing. Front Pharmacol 8:298

McClellan KJ, Markham A (1999) Finasteride: a review of its use in male pattern hair loss. Drugs

57:111–126

Mei F, Fancy SPJ, Shen Y-AA et al (2014) Micropillar arrays as a high-throughput screening

platform for therapeutics in multiple sclerosis. Nat Med 20:954–960

Mifepristone (2021) DrugBank online [Internet]. Available from: https://go.drugbank.com/drugs/

DB00834

Mirtazapine (2021) DrugBank online [Internet]. Available from: https://go.drugbank.com/drugs/

DB00370

70

I. A. Farouk et al.